APA (7th ed.) Citation

PE, S., JK, R., AF, L., Y, Y., D, W., B, T., . . . H, M. (2021). Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73(2), e485. https://doi.org/10.1093/cid/ciaa988

Chicago Style (17th ed.) Citation

PE, Sax, et al. "Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 73, no. 2 (2021): e485. https://doi.org/10.1093/cid/ciaa988.

MLA (9th ed.) Citation

PE, Sax, et al. "Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 73, no. 2, 2021, p. e485, https://doi.org/10.1093/cid/ciaa988.